CN100398526C - 作为用于治疗2型糖尿病和动脉粥样硬化的ppar调节剂的3-甲基-2-(3-(2-苯基-唑-4-基甲氧基)环己烷羰基-氨基)丁酸衍生物和相关化合物 - Google Patents

作为用于治疗2型糖尿病和动脉粥样硬化的ppar调节剂的3-甲基-2-(3-(2-苯基-唑-4-基甲氧基)环己烷羰基-氨基)丁酸衍生物和相关化合物 Download PDF

Info

Publication number
CN100398526C
CN100398526C CNB2004800054985A CN200480005498A CN100398526C CN 100398526 C CN100398526 C CN 100398526C CN B2004800054985 A CNB2004800054985 A CN B2004800054985A CN 200480005498 A CN200480005498 A CN 200480005498A CN 100398526 C CN100398526 C CN 100398526C
Authority
CN
China
Prior art keywords
oxazole
methyl
amino
acid
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800054985A
Other languages
English (en)
Chinese (zh)
Other versions
CN1756748A (zh
Inventor
C·斯塔普尔
D·格雷茨克
E·法尔克
J·格利策
S·凯尔
H-L·舍费尔
H·格隆比克
W·文德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN1756748A publication Critical patent/CN1756748A/zh
Application granted granted Critical
Publication of CN100398526C publication Critical patent/CN100398526C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CNB2004800054985A 2003-02-27 2004-02-19 作为用于治疗2型糖尿病和动脉粥样硬化的ppar调节剂的3-甲基-2-(3-(2-苯基-唑-4-基甲氧基)环己烷羰基-氨基)丁酸衍生物和相关化合物 Expired - Fee Related CN100398526C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308355.3 2003-02-27

Publications (2)

Publication Number Publication Date
CN1756748A CN1756748A (zh) 2006-04-05
CN100398526C true CN100398526C (zh) 2008-07-02

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB2004800054769A Expired - Fee Related CN100439347C (zh) 2003-02-27 2004-02-19 作为ppar调节剂用于治疗2型糖尿病和动脉粥样硬化的4-(3-(2-苯基噁唑-4-基甲氧基)-环己氧基)-丁酸衍生物及相关化合物
CNB2004800054379A Expired - Fee Related CN100439345C (zh) 2003-02-27 2004-02-19 作为用于治疗 2型糠尿病和动脉硬化症的ppar调节剂的 3 - ( 2 -苯基 -噁唑-4-基甲氧基)环己基甲氧基乙酸衍生物和相关化合物
CNB2004800054985A Expired - Fee Related CN100398526C (zh) 2003-02-27 2004-02-19 作为用于治疗2型糖尿病和动脉粥样硬化的ppar调节剂的3-甲基-2-(3-(2-苯基-唑-4-基甲氧基)环己烷羰基-氨基)丁酸衍生物和相关化合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CNB2004800054769A Expired - Fee Related CN100439347C (zh) 2003-02-27 2004-02-19 作为ppar调节剂用于治疗2型糖尿病和动脉粥样硬化的4-(3-(2-苯基噁唑-4-基甲氧基)-环己氧基)-丁酸衍生物及相关化合物
CNB2004800054379A Expired - Fee Related CN100439345C (zh) 2003-02-27 2004-02-19 作为用于治疗 2型糠尿病和动脉硬化症的ppar调节剂的 3 - ( 2 -苯基 -噁唑-4-基甲氧基)环己基甲氧基乙酸衍生物和相关化合物

Country Status (34)

Country Link
US (5) US7365084B2 (US07365084-20080429-C00069.png)
EP (3) EP1599455B1 (US07365084-20080429-C00069.png)
JP (3) JP2006519199A (US07365084-20080429-C00069.png)
KR (3) KR20050105492A (US07365084-20080429-C00069.png)
CN (3) CN100439347C (US07365084-20080429-C00069.png)
AR (3) AR043432A1 (US07365084-20080429-C00069.png)
AT (3) ATE365159T1 (US07365084-20080429-C00069.png)
AU (3) AU2004215673B2 (US07365084-20080429-C00069.png)
BR (3) BRPI0407814A (US07365084-20080429-C00069.png)
CA (3) CA2517381A1 (US07365084-20080429-C00069.png)
CL (2) CL2004000391A1 (US07365084-20080429-C00069.png)
CO (2) CO5690580A2 (US07365084-20080429-C00069.png)
DE (4) DE10308355A1 (US07365084-20080429-C00069.png)
DK (3) DK1599453T3 (US07365084-20080429-C00069.png)
EC (2) ECSP055985A (US07365084-20080429-C00069.png)
ES (3) ES2287700T3 (US07365084-20080429-C00069.png)
HR (3) HRP20050742A2 (US07365084-20080429-C00069.png)
IL (2) IL170314A (US07365084-20080429-C00069.png)
MA (3) MA27736A1 (US07365084-20080429-C00069.png)
MX (3) MXPA05008995A (US07365084-20080429-C00069.png)
NO (3) NO20054398L (US07365084-20080429-C00069.png)
OA (2) OA13034A (US07365084-20080429-C00069.png)
PA (1) PA8596801A1 (US07365084-20080429-C00069.png)
PE (3) PE20050293A1 (US07365084-20080429-C00069.png)
PL (3) PL378437A1 (US07365084-20080429-C00069.png)
PT (3) PT1599453E (US07365084-20080429-C00069.png)
RS (1) RS20050594A (US07365084-20080429-C00069.png)
RU (3) RU2005130002A (US07365084-20080429-C00069.png)
SA (1) SA04250153A (US07365084-20080429-C00069.png)
TN (2) TNSN05206A1 (US07365084-20080429-C00069.png)
TW (3) TW200510352A (US07365084-20080429-C00069.png)
UY (2) UY28210A1 (US07365084-20080429-C00069.png)
WO (3) WO2004076426A1 (US07365084-20080429-C00069.png)
ZA (2) ZA200505768B (US07365084-20080429-C00069.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
WO2008018138A1 (fr) 2006-08-10 2008-02-14 Wood One Co., Ltd. Composition hypoglycémique contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
CN105732376A (zh) 2007-08-16 2016-07-06 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
NZ587261A (en) 2008-02-29 2012-05-25 Nissan Chemical Ind Ltd Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
WO2019117317A1 (ja) 2017-12-13 2019-06-20 キヤノン株式会社 カートリッジ及び画像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
HUP0301101A3 (en) 1996-12-31 2009-03-30 Reddy S Res Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化1,2,4−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
KR100693771B1 (ko) * 1999-04-28 2007-03-12 사노피-아벤티스 도이칠란트 게엠베하 Ppar 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
CZ20013833A3 (cs) 1999-04-28 2002-02-13 Aventis Pharma Deutschland Gmbh Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
EP1194146B1 (en) 1999-06-18 2006-07-19 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
AU5784000A (en) 1999-07-09 2001-01-30 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
JP2003506365A (ja) 1999-07-29 2003-02-18 イーライ・リリー・アンド・カンパニー ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン:セロトニンアゴニスト
CZ2002767A3 (cs) * 1999-09-01 2002-06-12 Aventis Pharma Deutschland Gmbh Sulfonylkarboxamidové deriváty, způsob jejich přípravy a jejich pouľití jako léčiv
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
DE60008921T2 (de) 1999-12-03 2005-01-20 Astrazeneca Ab Kristalline form von (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenyl-ethoxy)phenyl]propansäure
IL151368A0 (en) 2000-03-31 2003-04-10 Probiodrug Ag Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
US6770133B2 (en) 2000-04-25 2004-08-03 Kyorin Pharmaceutical Co., Ltd. Stable crystal of thiazolidinedione derivative and process for producing the same
DK1277736T3 (da) 2000-04-28 2007-10-01 Asahi Kasei Pharma Corp Hidtil ukendte bicykliske forbindelser
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
YU91002A (sh) 2000-06-09 2006-05-25 Aventis Pharma Deutschland Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
CA2418104A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001284658A1 (en) 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
RS50864B (sr) 2000-12-21 2010-08-31 Sanofi-Aventis Deutschland Gmbh. Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
KR100635315B1 (ko) * 2000-12-25 2006-10-18 오노 야꾸힝 고교 가부시키가이샤 디히드로나프탈렌 유도체 화합물 및 이 화합물을 유효성분으로 하는 약제
BR0207285A (pt) * 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
KR20040030658A (ko) * 2001-06-07 2004-04-09 일라이 릴리 앤드 캄파니 페록시좀 증식제 활성화 수용체의 조절제
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
KR100915108B1 (ko) 2001-08-31 2009-09-03 사노피-아벤티스 도이칠란트 게엠베하 Ppar-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
EP1599452B1 (de) 2007-06-20
HRP20050744A2 (en) 2006-09-30
CO5690580A2 (es) 2006-10-31
CN1753879A (zh) 2006-03-29
US7335671B2 (en) 2008-02-26
DK1599453T3 (da) 2009-08-24
KR20050106461A (ko) 2005-11-09
WO2004076428A1 (de) 2004-09-10
CL2004000392A1 (es) 2005-04-22
US20080167354A1 (en) 2008-07-10
DE502004004139D1 (de) 2007-08-02
NO20054396D0 (no) 2005-09-22
US20050215596A1 (en) 2005-09-29
ECSP055986A (es) 2006-01-16
WO2004076426A1 (de) 2004-09-10
PL378130A1 (pl) 2006-03-06
ATE365159T1 (de) 2007-07-15
CA2516620A1 (en) 2004-09-10
CN1753881A (zh) 2006-03-29
MA27742A1 (fr) 2006-02-01
ATE430738T1 (de) 2009-05-15
OA13035A (en) 2006-11-10
UY28209A1 (es) 2004-09-30
ATE435217T1 (de) 2009-07-15
CA2517386A1 (en) 2004-09-10
CN1756748A (zh) 2006-04-05
JP2006519194A (ja) 2006-08-24
ECSP055985A (es) 2006-01-16
RS20050594A (en) 2007-12-31
DE502004009690D1 (de) 2009-08-13
EP1599455A1 (de) 2005-11-30
TW200508210A (en) 2005-03-01
PL377735A1 (pl) 2006-02-20
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
NO20054408D0 (no) 2005-09-22
AR043432A1 (es) 2005-07-27
AU2004215672B2 (en) 2010-01-07
OA13034A (en) 2006-11-10
EP1599453A1 (de) 2005-11-30
DK1599455T3 (da) 2009-11-09
MXPA05008951A (es) 2005-11-04
RU2005129995A (ru) 2006-01-27
JP2006519193A (ja) 2006-08-24
KR20050106462A (ko) 2005-11-09
EP1599452A1 (de) 2005-11-30
AU2004215673A1 (en) 2004-09-10
HRP20050742A2 (en) 2006-09-30
PT1599455E (pt) 2009-09-29
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
PE20050293A1 (es) 2005-05-24
US7872034B2 (en) 2011-01-18
EP1599453B1 (de) 2009-05-06
TW200510352A (en) 2005-03-16
AU2004215672A1 (en) 2004-09-10
BRPI0407907A (pt) 2006-02-14
US20050101637A1 (en) 2005-05-12
AU2004215673B2 (en) 2009-10-01
PL378437A1 (pl) 2006-04-03
BRPI0407814A (pt) 2006-02-14
UY28210A1 (es) 2004-09-30
US7365084B2 (en) 2008-04-29
US20080015238A1 (en) 2008-01-17
MA27737A1 (fr) 2006-02-01
MA27736A1 (fr) 2006-02-01
ZA200505768B (en) 2005-11-23
RU2005129992A (ru) 2006-02-10
CL2004000391A1 (es) 2005-01-07
JP2006519199A (ja) 2006-08-24
CA2517381A1 (en) 2004-09-10
BRPI0407758A (pt) 2006-02-14
ZA200505765B (en) 2006-05-31
DE502004009453D1 (de) 2009-06-18
PE20040959A1 (es) 2005-01-17
ES2329366T3 (es) 2009-11-25
CN100439347C (zh) 2008-12-03
MXPA05008995A (es) 2005-10-18
RU2005130002A (ru) 2006-01-27
MXPA05008988A (es) 2005-10-18
ES2326418T3 (es) 2009-10-09
EP1599455B1 (de) 2009-07-01
IL170314A (en) 2010-11-30
ES2287700T3 (es) 2007-12-16
NO20054396L (no) 2005-11-11
AR043427A1 (es) 2005-07-27
TNSN05204A1 (en) 2007-06-11
TNSN05206A1 (en) 2007-06-11
CO5690578A2 (es) 2006-10-31
DE10308355A1 (de) 2004-12-23
TW200500349A (en) 2005-01-01
KR20050105492A (ko) 2005-11-04
US7259177B2 (en) 2007-08-21
CN100439345C (zh) 2008-12-03
AU2004215677B2 (en) 2010-01-07
PT1599453E (pt) 2009-07-14
US20040209920A1 (en) 2004-10-21
NO20054398L (no) 2005-11-02
NO20054398D0 (no) 2005-09-22
AU2004215677A1 (en) 2004-09-10
AR043433A1 (es) 2005-07-27
DK1599452T3 (da) 2007-10-01
PE20050292A1 (es) 2005-05-24
WO2004076427A1 (de) 2004-09-10
PT1599452E (pt) 2007-09-12
SA04250153A (ar) 2005-12-03

Similar Documents

Publication Publication Date Title
CN100398526C (zh) 作为用于治疗2型糖尿病和动脉粥样硬化的ppar调节剂的3-甲基-2-(3-(2-苯基-唑-4-基甲氧基)环己烷羰基-氨基)丁酸衍生物和相关化合物
CN100439346C (zh) 二芳基环烷基衍生物、它们的产生方法以及它们作为药物的用途
CN101006066A (zh) 芳基环烷基取代的链烷酸衍生物、它们的制备方法和它们作为药物的用途
CN100398105C (zh) 含有酸性、主要是杂环基团的1,3-取代的环烷基衍生物,其相应的产生方法以及所述衍生物的制药用途
CN100417641C (zh) 作为ppar受体调节剂的具有支侧链的芳基环烷基衍生物,它们的制备方法和它们作为药物的用途
CN100469761C (zh) 环烷基-取代的链烷酸衍生物、其制备方法及其作为药物的用途
ES2330848T3 (es) Derivados de cicloalquilo con grupos acido carboxilico bioisostericos, procedimiento para su preparacion y su uso como medicamentos.
ES2335513T3 (es) Derivados del acido 2-(3-2-(fenil)-oxazol-4-ilmetoximetil)-ciclohexilmetoxi)-propionico en calidad de ligandos de ppar (receptores activadospor proliferadores de peroxisomas) para el tratamiento de la hiperlipidemia y la diabetes.
CN101193874A (zh) 作为ppar配体的6-唑-4-基甲氧基-烷氧基甲基取代的苯甲酸衍生物、其制备方法和其在药物制剂中的用途
US7173151B2 (en) Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
MX2007000913A (es) Derivados del acido 2-{3-2-(fenil)-oxazol-4-ilmetoximetil-ciclohexilmetoxi] propionico utilizados como ligandos de ppar (receptores activados del proliferador de peroxisomas) para el tratamiento de hiperlipidemia y diabetes.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1086831

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080702

Termination date: 20110219

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1086831

Country of ref document: HK